There is tremendous interest in the use of cannabinoids (including cannabidiol (CBD) and tetrahydrocannabinol (THC)) in the treatment of a variety of mental health conditions. In this comprehensive meta-analysis, the authors reviewed the data regarding symptom improvement, remission, global, functioning, quality of life, and patient/caregiver impression of change in depression, anxiety, psychosis, post-traumatic stress disorder (PTSD), attention-hyperactivity deficit disorder (ADHD), and Tourette syndrome. Except for a slight improvement in symptoms of anxiety, the analyzed data showed little symptom improvement related to use of CBD or THC and an increased risk of adverse effects compared with placebo (Table). Thus, despite the increased interest in use of CBD and THC in the treatment of mental health issues, there is little positive data available to recommend such treatments at this time.
Reference:
Black N et al. Lancet Psychiatry 2019;Epub ahead of print. Abstract
For more information: